IMUX is trading at 5.1% down now at $14.06 in pre-market, extending a pullback after a sharp run-up tied to its large private placement financing and transition toward commercialization. Recent coverage highlights heightened volatility around Immunic following a major funding deal supporting multiple sclerosis programs and longer-term clinical plans, with no fresh company-specific news emerging on July 2, 2026 to explain today’s move directly.